(Q37150326)

18 August 2017

1 reference

title

New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections (English)

1 reference

Mycobacterium tuberculosis

18 August 2017

main subject

0 references

author

Gurdyal Besra

5

1 reference

18 August 2017

Lynn G Dover

1

0 references

author name string

Apoorva Bhatt

2

1 reference

18 August 2017

Veemal Bhowruth

3

1 reference

18 August 2017

Benjamin E Willcox

4

1 reference

18 August 2017

publication date

1 May 2008

1 reference

Expert Review of Vaccines

18 August 2017

published in

1 reference

18 August 2017

volume

7

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

481-497

1 reference

Tuberculosis: latency and reactivation

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

On the nature of Mycobacterium tuberculosis-latent bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Dormancy of Mycobacterium tuberculosis and latency of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Nonreplicating persistence of mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

The action of antituberculosis drugs in short-course chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Basic Mechanisms of Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Patient adherence to tuberculosis treatment: a systematic review of qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Tuberculosis drug development pipeline: progress and hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Evolution of WHO policies for tuberculosis control, 1948-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Multidrug-resistant tuberculosis: this is the cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Biogenesis of the mycobacterial cell wall and the site of action of ethambutol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Interspecies pharmacokinetics and in vitro metabolism of SQ109.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Structure and mechanism of DNA topoisomerases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

DNA gyrase as a drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

DNA gyrase: structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

New 6-nitroquinolones: synthesis and antimicrobial activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Linezolid for the treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

First linezolid-resistant clinical isolates of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Antituberculosis activity of certain antifungal and antihelmintic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Altered expression profile of mycobacterial surface glycopeptidolipids following treatment with the antifungal azole inhibitors econazole and clotrimazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Characterization and catalytic properties of the sterol 14alpha-demethylase from Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Crystal structure of cytochrome P450 14 -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

A new class of antituberculosis agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Characterization of the cydAB-encoded cytochrome bd oxidase from Mycobacterium smegmatis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Chlorpromazine: A Drug Potentially Useful for Treating Mycobacterial Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

In-vitro and intracellular antimycobacterial activity of trifluoperazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

In vitro activities of peptide deformylase inhibitors against gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Peptide deformylase as an antibacterial drug target: target validation and resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Antibiotic Activity and Characterization of BB-3497, a Novel Peptide Deformylase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Characterization of a human peptide deformylase: implications for antibacterial drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Biosynthesis of 2-aceto-2-hydroxy acids: acetolactate synthases and acetohydroxyacid synthases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Characterization of acetohydroxyacid synthase from Mycobacterium tuberculosis and the identification of its new inhibitor from the screening of a chemical library

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

A flexible route to (5R)-thiolactomycin, a naturally occurring inhibitor of fatty acid synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Antitubercular agents. Part 2: new thiolactomycin analogues active against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Biphenyl-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Acetylene-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

X-Ray Crystal Structure of Mycobacterium tuberculosis β-Ketoacyl Acyl Carrier Protein Synthase II (mtKasB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Iron metabolism in pathogenic bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

A genetic locus required for iron acquisition in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Participation of fad and mbt genes in synthesis of mycobactin in Mycobacterium smegmatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Genes required for mycobacterial growth defined by high density mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

9-Benzylpurines with inhibitory activity against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Antimycobacterial activity of 9-sulfonylated/sulfenylated-6-mercaptopurine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Antimycobacterial agents. 1. Thio analogues of purine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Mycobacterium tuberculosis: here today, and here tomorrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Immunology of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Variation in protection by BCG: implications of and for heterologous immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

A review of vaccine research and development: tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Vaccine strategies against latent tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Advances in tuberculosis vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

The role of macrophage cell death in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

THP-1 cell apoptosis in response to Mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Comparative genomics of BCG vaccines by whole-genome DNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

DNA vaccines against mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Recognition of cluster of differentiation 1 antigens by human CD4-CD8-cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

CD1-restricted T cell recognition of microbial lipoglycan antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

T cell activation by lipopeptide antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Recognition of bacterial glycosphingolipids by natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Mechanism of thioamide drug action against tuberculosis and leprosy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Studies on cell-wall deficient non-acid fast variants of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.4.481

21 January 2018

Identifiers

DOI

10.1586/14760584.7.4.481

1 reference

18 August 2017

1 reference